Payment overview · 2025
General Payments
$131.00
5 reported records · 2 companies
Healthcare provider profile · identity verified
Daniel Kamara, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · LYNCHBURG, VA · NPI 1568028082
Verified facts
What the public records show
CMS Open Payments records show Daniel Kamara, NP received $131.00 in general payments during 2025 across 5 reported records.
Neurocrine BioSciences, Inc. accounted for 88.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Austedo by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $116.08 | 88.6% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $14.92 | 11.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $131.00 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $116.08 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $14.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 311 | 65 |
| Furosemide | Furosemide | 210 | 50 |
| Eliquis | Apixaban | 200 | 30 |
| Levothyroxine Sodium | Levothyroxine Sodium | 194 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 185 | 43 |
| Sertraline Hcl | Sertraline Hcl | 180 | 41 |
| Gabapentin | Gabapentin | 175 | 33 |
| Lorazepam | Lorazepam | 162 | 36 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 161 | 23 |
| Tramadol Hcl | Tramadol Hcl | 159 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 142 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 135 | 20 |
| Trazodone Hcl | Trazodone Hcl | 135 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 133 | 30 |
| Clozapine | Clozapine | 123 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 115 | 25 |
| Amlodipine Besylate | Amlodipine Besylate | 107 | 26 |
| Oxycodone Hcl | Oxycodone Hcl | 107 | 15 |
| Cephalexin | Cephalexin | 95 | 52 |
| Duloxetine Hcl | Duloxetine Hcl | 93 | 15 |
| Divalproex Sodium | Divalproex Sodium | 92 | 18 |
| Risperidone | Risperidone | 92 | 13 |
| Clonazepam | Clonazepam | 86 | suppressed |
| Pregabalin | Pregabalin | 81 | suppressed |
| Olanzapine | Olanzapine | 78 | 11 |
| Warfarin Sodium | Warfarin Sodium | 76 | suppressed |
| Mirtazapine | Mirtazapine | 73 | 18 |
| Buspirone Hcl | Buspirone Hcl | 72 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 14 |
| Lisinopril | Lisinopril | 72 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 17 |
| Prednisone | Prednisone | 68 | 27 |
| Metformin Hcl | Metformin Hcl | 65 | 13 |
| Myrbetriq | Mirabegron | 63 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 62 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 59 | 57 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 55 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 54 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 28 |
| Levofloxacin | Levofloxacin | 49 | 38 |
| Rexulti | Brexpiprazole | 47 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 46 | 12 |
| Potassium Chloride | Potassium Chloride | 45 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | 11 |
| Amoxicillin | Amoxicillin | 42 | suppressed |
| Baclofen | Baclofen | 42 | suppressed |
| Losartan Potassium | Losartan Potassium | 42 | suppressed |
| Methadone Hcl | Methadone Hcl | 42 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 20 |
| Albuterol Sulfate | Albuterol Sulfate | 40 | suppressed |
| Belsomra | Suvorexant | 40 | suppressed |
| Carvedilol | Carvedilol | 40 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 26 |
| Entresto | Sacubitril/Valsartan | 37 | suppressed |
| Torsemide | Torsemide | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Nystatin | Nystatin | 34 | 24 |
| Nyamyc | Nystatin | 33 | 21 |
| Acyclovir | Acyclovir | 32 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 32 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 22 |
| Latanoprost | Latanoprost | 31 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 29 | 17 |
| Ceftriaxone | Ceftriaxone Sodium | 29 | 17 |
| Finasteride | Finasteride | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Simvastatin | Simvastatin | 29 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 16 |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Bumetanide | Bumetanide | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 26 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 24 | suppressed |
| Enulose | Lactulose | 24 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 24 | suppressed |
| Austedo Xr | Deutetrabenazine | 23 | suppressed |
| Timolol Maleate | Timolol Maleate | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 21 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 21 | suppressed |
| Allopurinol | Allopurinol | 20 | suppressed |
| Austedo | Deutetrabenazine | 20 | suppressed |
| Fentanyl | Fentanyl | 20 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 17 |
| Permethrin | Permethrin | 20 | 15 |
| Spironolactone | Spironolactone | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 19 | 14 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 19 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 18 | 13 |
| Montelukast Sodium | Montelukast Sodium | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Ozempic | Semaglutide | 17 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Ivermectin | Ivermectin | 16 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 12 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | 13 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 13 | suppressed |
| Omeprazole | Omeprazole | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Budesonide | Budesonide | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Risperidone Odt | Risperidone | 12 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $131.00 · 5 records | Neurocrine BioSciences, Inc. | AUSTEDO XR, INGREZZA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Austedo Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Teva Pharmaceuticals USA, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error